Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envofolimab + Suvemcitug in Advanced Solid Tumors
NCT05148195Phase 2Terminated
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of suvemcitug in solid tumor, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Simcere Pharmaceutical Group. Started Dec 2021; status: terminated.
02
Drugs
suvemcitug
03
Conditions
solid tumorhepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05148195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148195.